Dimensional Fund Advisors LP Sells 38,927 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)

Dimensional Fund Advisors LP decreased its holdings in AnaptysBio, Inc. (NASDAQ:ANAB – Get Rating) by 4.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 884,014 shares of the biotechnology company’s stock after selling 38,927 shares during the period. Dimensional Fund Advisors LP owned approximately 3.13% of AnaptysBio worth $22,552,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in ANAB. US Bancorp DE lifted its stake in AnaptysBio by 44.4% in the 3rd quarter. US Bancorp DE now owns 1,538 shares of the biotechnology company’s stock valued at $39,000 after purchasing an additional 473 shares during the last quarter. Quantbot Technologies LP acquired a new position in shares of AnaptysBio in the second quarter valued at approximately $34,000. BNP Paribas Arbitrage SA raised its holdings in AnaptysBio by 75.4% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,984 shares of the biotechnology company’s stock valued at $101,000 after buying an additional 2,142 shares during the last quarter. The Manufacturers Life Insurance Company bought a new position in AnaptysBio in the 3rd quarter valued at approximately $211,000. Finally, Delphia USA Inc. bought a new position in shares of AnaptysBio during the first quarter valued at $233,000.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on ANAB shares. StockNews.com downgraded AnaptysBio from a “hold” rating to a “sell” rating in a report on Thursday, February 9th. JPMorgan Chase & Co. increased their target price on shares of AnaptysBio from $24.00 to $32.00 and gave the company an “underweight” rating in a research report on Friday, November 18th. Wedbush boosted their price target on shares of AnaptysBio from $21.00 to $32.00 in a research report on Wednesday, November 9th. Finally, Raymond James cut shares of AnaptysBio from an “outperform” rating to a “market perform” rating in a research report on Friday, January 6th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, AnaptysBio currently has an average rating of “Hold” and an average target price of $34.83.

AnaptysBio Stock Performance

AnaptysBio stock opened at $23.83 on Monday. The stock has a market capitalization of $665.57 million, a price-to-earnings ratio of -5.21 and a beta of -0.11. AnaptysBio, Inc. has a 52-week low of $18.20 and a 52-week high of $32.44. The stock’s 50 day moving average price is $25.94 and its two-hundred day moving average price is $26.63.

AnaptysBio Profile

(Get Rating)

AnaptysBio, Inc is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro.